Results of the Dyslipidemia International Study (DYSIS)-Middle East: Clinical Perspective on the Prevalence and Characteristics of Lipid Abnormalities in the Setting of Chronic Statin Treatment

Abstract

BackgroundTherapeutic intervention with low-density lipoprotein cholesterol-lowering agents known as statins has been demonstrated to reduce cardiovascular risk. However, many patients on statin treatment have persistent dyslipidemia and remain at a high risk of cardiovascular disease. Therefore, the objective of this study was to assess the frequency of lipid abnormalities in patients receiving chronic statin treatment.MethodsAs part of an international, cross-sectional, observational study, DYSIS-Middle East enrolled 2,182 patients in the United Arab Emirates (UAE), Saudi Arabia, Lebanon and Jordan. All patients were over 45 years of age and had been on statin treatment for at least three months. Data on demographics, lipid parameters and cardiovascular risk profile were recorded. Cardiovascular risk was defined according the guidelines of the European Society of Cardiology.ResultsThe majority of patients (82.6%) were classified as being at very high risk of cardiovascular events, and 61.8% of all patients did not attain LDL-C target levels. Low high-density lipoprotein cholesterol levels and elevated triglyceride levels were noted in 55.5% and 48.5% of patients, respectively. Multivariate logistical regression modeling indicated that factors independently associated with LDL-C levels not being at goal were lifestyle choices, diabetes mellitus, ischemic heart disease, and blood pressure ≥ 140/90 mmHg.ConclusionsAlmost two-thirds of statin-treated patients in the United Arab Emirates, Saudi Arabia, Lebanon and Jordan had inadequately controlled lipid levels. More comprehensive surveillance, awareness and treatment regimens, as well as modification of lifestyle choices, is necessary to halt the rise in cardiovascular disease-related mortality.

Efficacy of Statins in Dyslipidemia: A Non interventional comparative study in a tertiary care hospital, Ajman, UAE

“…Interethnic differences in statin efficacy in terms of differential LDL-C response to statin therapy have been documented in several pharmacologic investigations carried out among African-Americans, American Indians, Whites Hispanics and South Asians 16,17 . An international study from the Middle East region evaluating the frequency of lipid abnormalities in patients receiving statin treatment for long duration showed that almost two-thirds of statin-treated patients in the United Arab Emirates, Saudi Arabia, Lebanon and Jordan had inadequately controlled lipid levels 18 In this study the strongest variables associated with lipid abnormalities were current tobacco smoking and sedentary lifestyle 18 .…”

Statin-Associated Muscle Adverse Events: Update for clinicians

“…Results from the Dyslipidemia International Study-Middle East indicated that patients from the United Arab Emirates, Saudi Arabia, Lebanon and Jordan were most commonly prescribed statin doses at a potency equivalent to 40 mg/day and 80 mg/day of simvastatin. 13 This observation, along with the expanding indications for statins, are expected to lead to increases in the prevalence of statin-intolerant patients from the Arabian Gulf.…”

The Effectiveness of Outpatient and Hospital Lipid-Lowering Therapy in Patients With High and Very High Cardiovascular Risk During 2011-2015

“…Эффективность гиполипидемической терапии на амбулаторном и госпитальном этапах у пациентов высокого и очень высокого сердечно-сосудистого риска за период 2011-2015 гг. Рациональная фармакотерапия в кардиологии 2016;12 (6) Nowadays in spite of the fact that doctors have at their disposal effective and safe hypolipidemic agents, statins first of all, the problem of effective treatment of hypercholesterolaemia as one of major cardiovascular disease risk factors, often remains unsolved. This fact is proved by studies evaluated lipid-lowering therapy (LLT) efficiency in various countries including Russia [1][2][3].…”

“…In Russia 99.3% of patients, included into the study, were initially under lipid-lowering statin therapy, but the LDL cholesterol target levels, recommended by Russian Society of Cardiology in 2007, was reached only in 34.5% of participants [1]. DYSIS (Dyslipidaemia International Study) study revealed that LDL cholesterol target levels were not reached in 37-61.8% of patients in different countries of Europe, Canada, Middle East, Africa and Russia in 2011-2012 [5,6]. In Russia DYSIS study included 1586 outpatients with different cardiovascular risk categories under statin therapy.…”

“…Еще в одном исследовании -DYSIS (Dyslipidaemia International Study), которое также проходило преимуще-ственно в 2011-2012 гг. на территории Европы, Канады, Ближнего Востока, Африки и России, было показано, что про-цент недостижения целевых значений колебался от 37% до 61,8% в различных странах [5,6]. В исследовании DYSIS в России приняло участие 1586 амбулаторных пациентов с раз-личной степенью кардиоваскулярного риска, находящихся на терапии статинами.…”